source
- Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insuranceWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 7d ago↗ source
- FDA urges biosimilar sponsors to use alternative efficacy studies while AI reshapes regulatory workAI is becoming common in regulatory work. Experts say it will not replace regulatory professionals but will help them work more efficiently and free up time for human interaction. They stress that…